Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this research study is to determine whether the combination of inhaled amiloride and a concentrated salt solution is better than the salt solution itself for cystic fibrosis (CF) patients. In CF, airway secretions are thick and dehydrated. Many patients use inhaled salt solutions to help draw water into their secretions so that they are easier to get rid of with chest physiotherapy (“chest PT”) and cough. Unfortunately, these salt solutions are reabsorbed very quickly by the airways, so the beneficial effects may not last very long. In the hopes of prolonging their effects, the drug amiloride could be used in combination to slow salt and water reabsorption from airways. Amiloride is a medication that has been given by mouth for high blood pressure for many years. It is possible that the combination of salt solutions and inhaled amiloride may significantly improve the clearance of secretions in CF, which would be expected to improve lung function in CF.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
14 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Established diagnosis of CF
2 gene mutations identified, or
Sweat chloride > 60 mmol/L, and
1 or more typical CF clinical features
Age > 14 years
Able to perform spirometry and have post-bronchodilator FEV1 > 50% of predicted at screening
Oxyhemoglobin saturation (by pulse oximetry) > 92% on room air
Able to provide informed consent
Unstable lung disease:
FEV1 > 15% below best clinical measurement within 6 months
Requirement for IV antibiotics within 4 weeks of screening
Requirement for any change in pulmonary medication within 2 weeks of screening
Evidence of reactive airways
Clinical diagnosis of asthma
-> 15% increase in FEV1 after bronchodilator at screening
Hypertonic saline use within 2 weeks of screening
Unwilling or unable to either continue or discontinue cyclical therapies (e.g. inhaled tobramycin) for the 2 weeks prior to screening and the entire study period
Pregnancy, breast-feeding, or unwillingness to use barrier contraception during the entire study period
History of allergy or intolerance to amiloride, hypertonic saline, quinine, albuterol, or related compounds
Renal insufficiency (creatinine > 1.5 mg/dl)
Hyperkalemia (K+ > 5.0 meq/L)
Investigational drug use within 30 days of screening
Radiation exposure within the past year that would exceed Federal Regulations by participating in the study